The effects of sulfasalazine on human male fertility potential and seminal prostaglandins.
Fertility parameters of 10 men with chronic inflammatory bowel disease under treatment with sulfasalazine for at least 5 years were compared to those of 19 control subjects. Seminal parameters examined included ejaculate volume, sperm number and concentration, sperm motility index, sperm viability, pH, zinc concentration, prostaglandins E and F2-alpha, prolactin and 7 classes of sperm morphology. In addition, plasma concentrations of follicle-stimulating hormone, luteinizing hormone, testosterone and prolactin were noted. The data indicate that sulfasalazine therapy reduces semen quality and that this effect can be reversed upon removal from therapy. This reversal is independent of seminal prostaglandin concentrations.
D000328:Adult; D015237:Dinoprost; D015232:Dinoprostone; D005298:Fertility / Q000187:drug effects*; D005640:Follicle Stimulating Hormone / Q000032:analysis; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D007410:Intestinal Diseases / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000032:analysis; D008297:Male; D011388:Prolactin / Q000032:analysis; D011453:Prostaglandins / Q000032:analysis*; D011458:Prostaglandins E / Q000032:analysis; D011460:Prostaglandins F / Q000032:analysis; D012661:Semen / Q000032:analysis / Q000187:drug effects*; D013076:Sperm Count; D013081:Sperm Motility / Q000187:drug effects; D013094:Spermatozoa / Q000187:drug effects; D012460:Sulfasalazine / Q000009:adverse effects* / Q000627:therapeutic use; D013739:Testosterone / Q000032:analysis; D015032:Zinc / Q000032:analysis
D011453:Prostaglandins; D011458:Prostaglandins E; D011460:Prostaglandins F; D012460:Sulfasalazine; D013739:Testosterone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D015237:Dinoprost; D015032:Zinc; D015232:Dinoprostone